#United States #Breast Cancer #Saint Paul #Astrin Biosciences #Certitude™

Major Breakthrough in Breast Cancer Detection

Astrin Biosciences has made a significant leap in breast cancer screening with the launch of its novel "Certitude™" blood test, now accessible to an impressive 75 million women through a collaboration with OpenLoop Health. This first-of-its-kind non-imaging test is designed to detect early signs of breast cancer, filling a critical gap in the healthcare landscape, especially for women with dense breast tissue.

Why This Test Matters

Traditionally, women classified with dense breast tissue have faced considerable challenges when it comes to early detection of breast cancer. Standard imaging methods often fall short in such cases, meaning that many women may not receive the necessary screenings in a timely manner. The Certitude™ test addresses this issue by providing a supplemental screening tool that uses a simple blood sample to identify potential early molecular signals associated with breast cancer.

Dr. Tanya Gupta, Medical Director at Astrin Biosciences, commented on the importance of the test, stating that it offers an additional data point for individuals with dense tissue, which can complicate imaging results. "Certificates provides a data point from a simple blood sample that may help patients and their physicians better understand their individual risk," Dr. Gupta explained.

Enhanced Accessibility Through Telehealth

One of the standout features of the Certitude™ test is its integration with telehealth capabilities. This partnership allows women to access screening from the comfort of their homes, effectively removing barriers imposed by geography and lack of access to specialists. Jayant Parthasarathy, CEO of Astrin Biosciences, emphasized that this initiative is about increasing accessibility: "For too long, geography and fragmented access have stood between women and the comprehensive screening they deserve."

Jon Lensing, CEO and Co-Founder of OpenLoop Health, echoed this sentiment, asserting that access to care should not be dependent on one’s zip code. "Certitude is a meaningful new tool that will enable more women to get answers without waiting for the right specialist to be nearby," he noted.

How the Test Works

The Certitude™ test utilizes Astrin's proprietary deep proteomic platform, which analyzes thousands of proteins from a small blood sample to identify constituents that may indicate breast cancer. According to validation studies involving 1,242 women, the test has shown remarkable results, achieving 92% sensitivity and 93% specificity in detecting various breast cancer stages and subtypes, with a negative predictive value exceeding 99.9%.

This level of accuracy represents a substantial improvement over traditional breast cancer screening methods, underscoring the game's changing potential of the Certitude™ test.

A Bright Future for Women’s Health

With the introduction of the Certitude™ test, Astrin Biosciences hopes to bring more certainty to the screening process, transforming what is typically a stressful and uncertain journey into one of confidence and reassurance for women. Women in the United States can check if they are eligible for the test and order it online, enabling them to take proactive steps toward their health.

In conclusion, as breast cancer continues to impact many lives, advancements like the Certitude™ blood test pave the way for more effective and accessible screening solutions. By empowering women with new opportunities to monitor their health, Astrin Biosciences is setting a new standard for what can be achieved in cancer diagnostics. For interested individuals, further details can be found at www.certitudetest.com.